title: [Influence of OK-432 on intratumor 5-fluorouracil concentration in cases given UFT].
abstract: The influence of OK-432 on the activation of UFT, consisting of tegafur and Uracil, was examined in patients with gastric cancer and colonic cancer. In 14 gastric cancer and 15 colonic cancer cases, to which UFT 400 mg/day and OK-432 2KE 2/W were administered orally and intra-muscularly for 2 weeks preoperatively until surgical treatment, intratumor 5-fluorouracil (5-FU) concentration was measured and compared with that of patients who given UFT 400 mg/day orally for 2 weeks (15 gastric cancer and 15 colonic cancer cases). As the results, in the groups of patients given OK-432, the concentration in gastric cancer tissue was 0.093 +/- 0.067 microgram/g and that in colonic cancer was 0.098 +/- 0.058 microgram/g. Both values exceeded 0.05 microgram/g which is considered to be the effective intratumor 5-FU concentration. No difference was observed in these cases given UFT alone. The ratio of intratumor 5-FU concentration vs. that of normal tissue was 2.5 for gastric cancer and 2.7 for colonic cancer and the ratio of tumor vs. serum 5-FU concentrations was 8.5 for gastric cancer and 10.9 for colonic cancer. No difference was also observed in these values in cases given UFT alone. From above results, it seemed that the clinical dose of OK-432 2KE 2/W had no influence on the activation of UFT, so that the combination therapy of UFT and OK-432 was found to be clinically useful.
authors.affiliation: Dept. of Surgery, Yokosuka Kyosai Hospital.
authors.forename: K
authors.initials: K
authors.lastname: Sinmyo
authors.forename: H
authors.initials: H
authors.lastname: Hosoi
authors.forename: H
authors.initials: H
authors.lastname: Suwa
authors.forename: M
authors.initials: M
authors.lastname: Kitagawa
authors.forename: K
authors.initials: K
authors.lastname: Yamaguchi
authors.forename: H
authors.initials: H
authors.lastname: Susaki
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001688:Biological Products / Q000494:pharmacology*; D001711:Biotransformation; D003110:Colonic Neoplasms / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D005472:Fluorouracil / Q000032:analysis* / Q000097:blood; D006801:Humans; D008207:Lymphatic Metastasis; D010844:Picibanil / Q000008:administration & dosage / Q000494:pharmacology*; D013274:Stomach Neoplasms / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage / Q000493:pharmacokinetics; D014018:Tissue Distribution; D014498:Uracil / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D001688:Biological Products; D005641:Tegafur; D010844:Picibanil; D014498:Uracil; D005472:Fluorouracil